Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 83 results for colitis

  1. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  2. Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal (IPG642)

    Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal in adults. This involves using the ileum to create a pouch on the inside of the abdominal wall to collect waste.

    Interventional procedures guidance
    Published
    20 February 2019
    View recommendations

    Sections for IPG642

  6. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. What is the effectiveness of oral tacrolimus and systemic (intramuscular/subcutaneous/oral) methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates?

    methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates? Any explanatory...

    Research recommendation
    Published
    25 October 2019

  8. What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition to aminosalicylates compared with each other and with aminosalicylate monotherapy for the induction of remission for people with mild-to-moderate ulcerative colitis?

    the induction of remission for people with mild-to-moderate ulcerative colitis? Any explanatory notes(if applicable) To find out why the...

    Research recommendation
    Published
    25 October 2019

  9. What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction of remission for people with moderate ulcerative colitis?

    ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...

    Research recommendation
    Published
    25 October 2019

  10. What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone plus an aminosalicylate for induction of remission for people with moderate ulcerative colitis?

    ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...

    Research recommendation
    Published
    25 October 2019

  11. What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?

    placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids? Any...

    Research recommendation
    Published
    25 October 2019

  12. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  13. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  14. Spondyloarthritis (QS170)

    This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    28 June 2018
    View quality statements

    Sections for QS170

  15. Adenoma types and risk of colorectal cancer:- Does the risk of colorectal cancer depend on the type of adenoma?

    cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued

    Research recommendation
    Published
    9 June 2015